How much for all of that?
What about some information that is not passed on so quickly – for a fee? With all that is at stake, COVID-19 immunity feels a bit like an unaffordable commodity.
Pricing a vaccine isn’t as complicated as creating a vaccine, but it’s not that far away. To fight the coronavirus, the vaccine has to be cheap and available in large quantities so that everyone can get a dose. But it also has to make enough profit to cover the costs of development and manufacture. On August 5th, investors are calling NPR Moderna CEO reportedly said the company had already signed contracts with some countries for $ 32 and $ 37 per dose for small orders, with prices lower for larger quantities.
How is Inovio doing balancing on this slim wire rope? Broderick said she thinks it̵
The process of making DNA is actually not that dissimilar to brewing beer, she said, but instead of eating yeast sugar and leaving alcohol behind, you have E. coli bacteria that act as a mini-factory to make the vaccine. Injecting pieces of DNA made by bacteria into human cells may sound a bit strange, but it’s actually not a new concept. The production and addition of DNA to cells has long been an important skill in basic scientific research – this is just a reuse of existing technology.
With the exception of a special use waiver in China, no vaccine is currently available to the public. But if you’re interested in stretching your arm for science, Broderick said you can take part in the clinical trials. Inovio’s website has one shortcut This will take you to the government’s page where you can join the waiting list. The vaccine cannot be developed further without further testing and more test subjects.
A clinical study is a controlled scientific study. Registration does not guarantee acceptance. And because half of the participants get a sham vaccine, taking part in the study doesn’t mean they are actually vaccinated.
COVID-19 has not affected everyone equally. The elderly are particularly at risk, and blacks and Latinos, many of whom are key occupations during the pandemic, have become sick and died more often.
“When testing [of] The vaccine doesn’t really reflect demographics, the population it was designed for, it’s almost the wrong picture, ”Broderick said. Inovio is trying to address this in its experimental design, she said.
“We were very, very aware that we were moving forward for our next round of clinical trials. It is that these groups are actively encouraged to participate in the clinical trial.”
Daniel Kulp, a researcher at Wistar who continues to work on the COVID-19 vaccine, believes there will be many different vaccines available.
“I think this is also an advantage,” said Kulp, “because they will all differ slightly, what kind of immunity they drive and what safety profile they have.”
With so many vaccines emerging, the best case scenario is that people around the world will have access to several safe options as soon as possible. Not just for Inovio, but also for her personally, that’s huge, said Broderick.
“As a mother, as a citizen, you can’t help but be moved by the situation we are in, in which the whole world is right now,” she said.
Patel also sees the importance of work. “When we have a vaccine that, along with other candidates, we believe will help people feel more comfortable and get them back into their normal lives and be the social people we are.”